AR020091A1 - Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y - Google Patents

Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y

Info

Publication number
AR020091A1
AR020091A1 ARP990102948A ARP990102948A AR020091A1 AR 020091 A1 AR020091 A1 AR 020091A1 AR P990102948 A ARP990102948 A AR P990102948A AR P990102948 A ARP990102948 A AR P990102948A AR 020091 A1 AR020091 A1 AR 020091A1
Authority
AR
Argentina
Prior art keywords
virus
vaccines
vaccine
ndv
cdna
Prior art date
Application number
ARP990102948A
Other languages
English (en)
Spanish (es)
Original Assignee
Stichting Dienst Landbouwkundi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Dienst Landbouwkundi filed Critical Stichting Dienst Landbouwkundi
Publication of AR020091A1 publication Critical patent/AR020091A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP990102948A 1998-06-19 1999-06-18 Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y AR020091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98202054A EP0974660A1 (en) 1998-06-19 1998-06-19 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Publications (1)

Publication Number Publication Date
AR020091A1 true AR020091A1 (es) 2002-04-10

Family

ID=8233832

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102948A AR020091A1 (es) 1998-06-19 1999-06-18 Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y

Country Status (28)

Country Link
US (3) US6719979B2 (enExample)
EP (2) EP0974660A1 (enExample)
JP (3) JP2002518012A (enExample)
KR (1) KR20010053000A (enExample)
CN (2) CN101275142A (enExample)
AR (1) AR020091A1 (enExample)
AT (1) ATE367442T1 (enExample)
AU (1) AU754844B2 (enExample)
BR (1) BR9911383A (enExample)
CA (1) CA2334165A1 (enExample)
CZ (1) CZ300760B6 (enExample)
DE (1) DE69936585T2 (enExample)
DK (1) DK1088077T3 (enExample)
EA (1) EA004796B1 (enExample)
ES (1) ES2291029T3 (enExample)
HR (1) HRP20010042B1 (enExample)
HU (1) HUP0102429A3 (enExample)
ID (1) ID27343A (enExample)
IL (2) IL140381A0 (enExample)
NO (1) NO329193B1 (enExample)
NZ (1) NZ508982A (enExample)
PL (1) PL197722B1 (enExample)
PT (1) PT1088077E (enExample)
SI (1) SI1088077T1 (enExample)
TR (1) TR200100350T2 (enExample)
UA (1) UA77146C2 (enExample)
WO (1) WO1999066045A1 (enExample)
ZA (1) ZA200100241B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
AU4971500A (en) * 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
EP1074614B1 (en) * 1999-07-27 2004-07-07 Akzo Nobel N.V. A recombinant Newcastle disease virus for in ovo vaccination
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
AU2001263896A1 (en) 2000-06-23 2002-01-14 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
WO2002036617A2 (en) * 2000-11-02 2002-05-10 Akzo Nobel N.V. A recombinant newcastle disease virus nucleoprotein mutant as a marker vaccine
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
ATE307606T1 (de) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
EP1485488A4 (en) * 2002-02-21 2005-03-02 Sinai School Medicine RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
KR20060035596A (ko) 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
KR20060029214A (ko) * 2003-05-05 2006-04-05 다우 아그로사이언시즈 엘엘씨 이식 유전자 식물 세포들로부터 유래된 안정한 면역예방적및 치료적 조성물들 및 생산방법
AU2004249802B2 (en) 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
KR20090007706A (ko) * 2006-03-15 2009-01-20 인터벳 인터내셔널 비.브이. 조류 인플루엔자 바이러스의 ｈ5 헤마글루티닌을 발현하는 재조합 뉴캐슬병 바이러스
AU2007226555B2 (en) * 2006-03-15 2012-07-05 Intervet International B.V. Recombinant Mononegaviral virus vectors
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
KR101745029B1 (ko) * 2009-08-21 2017-06-08 메리얼 인코포레이티드 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
CN110777124A (zh) 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
HRP20190525T4 (hr) 2011-11-30 2023-01-20 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
SG10202108573TA (en) 2016-02-03 2021-09-29 Cg Discovery Inc Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
AU2019227531B2 (en) * 2018-02-28 2025-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
CA3106170A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
US11334671B2 (en) * 2019-10-14 2022-05-17 International Business Machines Corporation Adding adversarial robustness to trained machine learning models
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用
CN121285568A (zh) 2023-03-30 2026-01-06 制药五有限责任公司 编码视杆细胞源性视锥细胞活力因子和人IgK信号序列的载体
WO2026072752A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
DK0702085T4 (da) * 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
EP0780475B2 (en) * 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Also Published As

Publication number Publication date
WO1999066045A1 (en) 1999-12-23
EP1088077B2 (en) 2012-03-21
SI1088077T1 (sl) 2008-02-29
JP2006141398A (ja) 2006-06-08
CZ300760B6 (cs) 2009-08-05
HUP0102429A3 (en) 2003-12-29
AU754844B2 (en) 2002-11-28
IL140381A (en) 2008-06-05
TR200100350T2 (tr) 2001-06-21
DE69936585T2 (de) 2008-04-30
PL348300A1 (en) 2002-05-20
EP0974660A1 (en) 2000-01-26
NO20006406D0 (no) 2000-12-15
CN1314942A (zh) 2001-09-26
AU4399199A (en) 2000-01-05
NZ508982A (en) 2003-07-25
NO329193B1 (no) 2010-09-13
DK1088077T3 (da) 2007-11-12
KR20010053000A (ko) 2001-06-25
UA77146C2 (en) 2006-11-15
US6719979B2 (en) 2004-04-13
IL140381A0 (en) 2002-02-10
ZA200100241B (en) 2002-06-26
HUP0102429A2 (hu) 2001-10-28
ATE367442T1 (de) 2007-08-15
EA004796B1 (ru) 2004-08-26
US20040234552A1 (en) 2004-11-25
CA2334165A1 (en) 1999-12-23
HRP20010042B1 (en) 2011-03-31
ID27343A (id) 2001-04-05
US7547442B2 (en) 2009-06-16
DE69936585D1 (de) 2007-08-30
HRP20010042A2 (en) 2001-12-31
NO20006406L (no) 2001-02-19
ES2291029T3 (es) 2008-02-16
EA200100057A1 (ru) 2001-08-27
BR9911383A (pt) 2001-03-13
JP2002518012A (ja) 2002-06-25
JP2009261387A (ja) 2009-11-12
US20030087417A1 (en) 2003-05-08
CN101275142A (zh) 2008-10-01
PT1088077E (pt) 2007-10-29
CZ20004707A3 (en) 2001-05-16
EP1088077A1 (en) 2001-04-04
US20040235134A1 (en) 2004-11-25
EP1088077B1 (en) 2007-07-18
US7332169B2 (en) 2008-02-19
PL197722B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
BR9911383A (pt) Cdna de paramyxovirus de ave, rna, processo para gerar cópia infecciosa do paramyxovirus de ave e para distinguir animais não vacinados ou animais vacinados com uma vacina do ndv, cópia infecciosa do paramyxovirus de ave, vacina, e, conjunto de diagnóstico.
AR008620A1 (es) Vacuna viva recombinante, fragmento de adn y virus iltv que la componen
Matsuno et al. A candidate for a new serotype of human rotavirus
Sun et al. Genotypic evolution and antigenic drift of H9N2 influenza viruses in China from 1994 to 2008
Gohm et al. Detection of Newcastle disease virus in organs and faeces of experimentally infected chickens using RT-PCR
Gelb Jr et al. Characterization of nephropathogenic infectious bronchitis virus DMV/1639/11 recovered from Delmarva broiler chickens in 2011
Markis Evaluation of pathogenicity and antigenicity of avian reoviruses and disease control through vaccination
CY1106493T1 (el) Μεταλλαγμενη μορφη νουκλεοπρωτεϊνης ανασυνδυασμενου ιου ασθενειας του newcastle ως εμβολιο δεικτης
Zhao et al. Efficacy of an inactivated bivalent vaccine against the prevalent strains of Newcastle disease and H9N2 avian influenza
CO4650230A1 (es) Vacuna viva recombinante aviaria, utilizando como vector el virus de la laringotraqueitis infecciosa aviaria
Chen et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate
BR9812845A (pt) Circovìrus suìnos, vacinas e reagentes de diagnóstico
Zhou et al. Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120
Jackwood et al. Attenuation, safety, and efficacy of an infectious bronchitis virus GA98 serotype vaccine
Wang et al. Changes in VP2 gene during the attenuation of very virulent infectious bursal disease virus strain Gx isolated in China
Crispo et al. Partial molecular characterization and pathogenicity study of an avian reovirus causing tenosynovitis in commercial broilers
HUT52555A (en) Process for production of virus and vaccina against recombinant marek-desease
Alvarado et al. Evaluation of the protection conferred by commercial vaccines against the California 99 isolate of infectious bronchitis virus
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
Jackwood et al. Pathogenicity of genome reassortant infectious bursal disease viruses in chickens and turkeys
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus
Habib et al. Immunogenicity of formaldehyde and binary ethylenimine inactivated infectious bursal disease virus in broiler chicks
CA2412075A1 (en) Attenuated bovine respiratory syncytial virus

Legal Events

Date Code Title Description
FC Refusal